Janus Henderson Group’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98.1M | Sell |
3,410,320
-14,122
| -0.4% | -$406K | 0.05% | 264 |
|
|
2025
Q1 | $119M | Buy |
3,424,442
+629,001
| +23% | +$21.8M | 0.07% | 241 |
|
|
2024
Q4 | $143M | Buy |
2,795,441
+365,991
| +15% | +$18.7M | 0.07% | 233 |
|
|
2024
Q3 | $124M | Sell |
2,429,450
-26,211
| -1% | -$1.34M | 0.06% | 249 |
|
|
2024
Q2 | $110M | Buy |
2,455,661
+477,489
| +24% | +$21.4M | 0.06% | 251 |
|
|
2024
Q1 | $92.5M | Buy |
1,978,172
+1,434,909
| +264% | +$67.1M | 0.05% | 275 |
|
|
2023
Q4 | $19.3M | Sell |
543,263
-45,115
| -8% | -$1.6M | 0.01% | 557 |
|
|
2023
Q3 | $17.5M | Buy |
588,378
+117,642
| +25% | +$3.49M | 0.01% | 560 |
|
|
2023
Q2 | $8.48M | Buy |
470,736
+54,484
| +13% | +$981K | 0.01% | 723 |
|
|
2023
Q1 | $6.69M | Buy |
416,252
+9,988
| +2% | +$160K | ﹤0.01% | 796 |
|
|
2022
Q4 | $7.43M | Buy |
406,264
+26,568
| +7% | +$486K | 0.01% | 780 |
|
|
2022
Q3 | $7.46M | Buy |
+379,696
| New | +$7.46M | ﹤0.01% | 895 |
|
|
2020
Q2 | – | Sell |
-491,691
| Closed | -$7.23M | – | 1321 |
|
|
2020
Q1 | $7.23M | Buy |
491,691
+2,819
| +0.6% | +$41.4K | 0.01% | 855 |
|
|
2019
Q4 | $12.3M | Sell |
488,872
-7,788
| -2% | -$195K | 0.01% | 926 |
|
|
2019
Q3 | $7.47M | Sell |
496,660
-2,882
| -0.6% | -$43.3K | ﹤0.01% | 1000 |
|
|
2019
Q2 | $12.5M | Buy |
499,542
+11,175
| +2% | +$279K | 0.01% | 902 |
|
|
2019
Q1 | $11.1M | Sell |
488,367
-41,459
| -8% | -$944K | 0.01% | 903 |
|
|
2018
Q4 | $15.9M | Buy |
529,826
+5,082
| +1% | +$152K | 0.01% | 804 |
|
|
2018
Q3 | $15M | Buy |
+524,744
| New | +$15M | 0.01% | 862 |
|